Y-mAbs Therapeutics Inc. (YmAbs) is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer based on a range of technologies licensed from Memorial Sloan Kettering Cancer Center. Its mission is to become the world leader in developing better and safer antibody-based pediatric oncology products addressing clear unmet medical needs. YmAbs also seeks to advance and expand its product pipeline into certain adult cancer indications and to leverage its extensive drug development capabilities and platform technology towards the creation of new types of bispecific antibodies.
Copyright West LLC. Minimum 15 minutes delayed.
Sep 25, 2018Y-mAbs Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Sep 20, 2018Y-mAbs Therapeutics Announces Pricing of Initial Public Offering
Aug 21, 2018Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma
More events are coming soon.